Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-IBS-D study of Brenipatide in adults with IBS-D
2025-524973-17-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in Diarrhea-predominant irritable bowel syndrome (IBS-D) comparing Brenipatide with Placebo to match LY (2 arms). Primary endpoint: Daily composite response on at least 50% of days. Planned start Aug 2026; status: authorised.
02
Drugs
brenipatide
03
Conditions
Diarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on 2025-524973-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524973-17-00.